Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma

Corbett, R, Pinkerton, R, Pritchard, J, Meller, S, Lewis, I, Kingston, J and McElwain, T (1992) Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. European Journal of Cancer, 28 8-9: 1324-1328. doi:10.1016/0959-8049(92)90509-Z


Author Corbett, R
Pinkerton, R
Pritchard, J
Meller, S
Lewis, I
Kingston, J
McElwain, T
Title Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma
Journal name European Journal of Cancer   Check publisher's open access policy
ISSN 0959-8049
Publication date 1992-01-01
Year available 1992
Sub-type Article (original research)
DOI 10.1016/0959-8049(92)90509-Z
Open Access Status Not yet assessed
Volume 28
Issue 8-9
Start page 1324
End page 1328
Total pages 5
Publisher PERGAMON-ELSEVIER SCIENCE LTD
Language eng
Subject 1306 Cancer Research
2720 Hematology
2730 Oncology
Abstract The efficacy and toxicity of a high-dose multiagent consolidation regimen, OMEC (vincristine, melphalan, etoposide and carboplatin), with autologous bone marrow rescue was studied in patients with poor-prognosis neuroblastoma. 20 patients were treated with OMEC, 18 after induction chemotherapy and 2 following relapse. All patients received, per m2, vincristine 4 mg, etoposide 1 g, carboplatin 1.0-1.75 g and melphalan 180 mg followed by bone marrow rescue. 4 patients (20%) died of treatment-related complications. Severe gastrointestinal toxicity occurred in all of these patients, and in 75% of patients overall. 1 of 5 patients with evaluable disease achieved complete remission. 13 patients (65%) have relapsed a median of 10 months (range 3-26) after receiving OMEC. Thus, OMEC was not more effective, yet more toxic, than high-dose melphalan given alone, and the use of similar multiagent regimens with overlapping toxicities in advanced neuroblastoma appears inadvisable.
Keyword Oncology
Oncology
ONCOLOGY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 27 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 26 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 03:31:05 EST by System User